Biogen Inc.
Biogen Inc. (BIIB) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · BIIB · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
4
12 Months
Buy/Sell ratio
0.25
Buy/Sell (by trades)
Overall sentiment
Biogen Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
BIIB insider buying and selling by quarter
BIIB insider selling · BIIB insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · BIIB ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
BIIB executive sell shares · BIIB board member insider trading · BIIB insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 1, 2026 | Keeney Adam Head of Corporate Development | Option | 939 | — | Form 4 |
| May 1, 2026 | Keeney Adam Head of Corporate Development | Other | 455 | $85K | Form 4 |
| Apr 1, 2026 | Godbout Sean CAO | Option | 181 | — | Form 4 |
| Apr 1, 2026 | Godbout Sean CAO | Other | 54 | $10K | Form 4 |
| Feb 12, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Purchase | 3 | $585 | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Option | 15,453 | — | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Other | 6,624 | $1.33M⚡ | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Option | 9,008 | — | Form 4 |
| Feb 6, 2026 | Viehbacher Christopher President and CEO · Director | Other | 4,356 | $876K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Option | 4,683 | — | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Other | 1,412 | $284K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Option | 2,217 | — | Form 4 |
| Feb 9, 2026 | Singhal Priya Head of Development | Sale | 2,660 | $532K | Form 4 |
| Feb 6, 2026 | Singhal Priya Head of Development | Other | 1,056 | $212K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 4,683 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 1,408 | $283K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 1,940 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 914 | $184K | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Option | 2,102 | — | Form 4 |
| Feb 6, 2026 | Murphy Nicole Head of Pharm Ops and Tech | Other | 1,017 | $205K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 3,511 | — | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Other | 1,063 | $214K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 703 | — | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Other | 207 | $42K | Form 4 |
| Feb 6, 2026 | Kramer Robin CFO | Option | 789 | — | Form 4 |
Keeney Adam
Head of Corporate Development
Date
May 1
Shares
455
Price
$187.06
Value
$85K
Murphy Nicole
Head of Pharm Ops and Tech
Date
Feb 12
Shares
3
Price
$195.03
Value
$585
Viehbacher Christopher
President and CEO · Director
Date
Feb 6
Shares
15,453
Price
—
Value
—
Viehbacher Christopher
President and CEO · Director
Date
Feb 6
Shares
6,624
Price
$201.18
Value
$1.33M ⚡
Viehbacher Christopher
President and CEO · Director
Date
Feb 6
Shares
9,008
Price
—
Value
—
Viehbacher Christopher
President and CEO · Director
Date
Feb 6
Shares
4,356
Price
$201.18
Value
$876K
Singhal Priya
Head of Development
Date
Feb 6
Shares
1,412
Price
$201.18
Value
$284K
Singhal Priya
Head of Development
Date
Feb 9
Shares
2,660
Price
$199.83
Value
$532K
Singhal Priya
Head of Development
Date
Feb 6
Shares
1,056
Price
$201.18
Value
$212K
Murphy Nicole
Head of Pharm Ops and Tech
Date
Feb 6
Shares
1,408
Price
$201.18
Value
$283K
Murphy Nicole
Head of Pharm Ops and Tech
Date
Feb 6
Shares
914
Price
$201.18
Value
$184K
Murphy Nicole
Head of Pharm Ops and Tech
Date
Feb 6
Shares
1,017
Price
$201.18
Value
$205K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About BIIB insider trading
BIIB insider trades
Biogen Inc. (BIIB) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Godbout Sean (CAO), Singhal Priya (Head of Development), Murphy Nicole (Head of Pharm Ops and Tech). Over the past 12 months, 5 insiders have filed transactions with the SEC. BIIB insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Biogen Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
BIIB insider trading · 5 questionsThe insiders of Biogen Inc. (BIIB) include executives and directors such as Godbout Sean (CAO), Singhal Priya (Head of Development), Murphy Nicole (Head of Pharm Ops and Tech), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026